biostudies-literatureUnknown44(2)Radcliffe CDirect acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.Clinics in chest medicine279-297https://www.ebi.ac.uk/biostudies/studies/S-EPMC9701636biostudies-literatureAntiviral Treatment of Coronavirus Disease-2019 Pneumonia.PMC9701636Malinis MRadcliffe CAzar MMfalseAntiviral Treatment of Coronavirus Disease-2019 Pneumonia.Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.2023-01-01T00:00:00Z2023 Jun2025-04-19T22:46:46.046Z2025-04-19T22:46:46.046ZS-EPMC97016363708522010.1016/j.ccm.2022.11.008